

OSLO CANCER



Oslo Cancer Cluster invites you to join

Cancer Crosslinks 2023 - the 15th Edition

January 26, 2023

New dimensions to the hallmarks of cancer: How is the last decade of discoveries advancing our understanding of cancer biology and transforming precision medicine?

You are invited to join distinguished speakers from the UK, USA, Germany, Switzerland and Sweden as they address recent progress in the understanding of tumor evolution and emerging diagnostic and treatment options for solid and hematological cancers.

Daytime

Thursday, January 26, 2023 at Oslo Cancer Cluster Innovation Park 10:30 - 16:15 (CET) Educational Program (with digital option) 16:15+ (CET) Afternoon Networking Event

Speakers & Topics

- Douglas Hanahan, Ludwig Institute for Cancer Research & Swiss Federal Institute of Technology, Switzerland The Hallmarks of Cancer: New Dimensions - Integrating Pre-Clinical and Clinical Cancer Trials of Mechanism-Targeted Therapies
- Mariam Jamal-Hanjani, CRUK Lung Cancer Centre of Excellence & UCL Hospital, UK The natural history of non-small cell lung cancer evolution in TRACERx
- Nilofer Azad, Johns Hopkins University & Sidney Kimmel Comprehensive Cancer Center, USA Epigenetic (Combination) Therapy – exploiting complex biology to offer novel treatment options for patients with GI cancers
- Alpaslan (Aslan) Tasdogan, University Hospital Essen & German Cancer Consortium, Germany The metabolic regulation of cancer progression
- Thomas Nerreter, University Hospital & CCC Würzburg, Germany Cellular Therapy for solid and hematological tumors: novel targets and technologies
- Tom Erkers, Karolinska Institute, Stockholm, Sweden Data-driven hallmarks of acute myeloid leukemia: biological, prognostic and therapeutic implications
- Jakob Nikolas Kather, Technical University Dresden, Germany Al biomarkers in cancer: recent progress and the way to clinical implementation


Afternoon

Starting at 16:15 (CET) On-Site Networking Event

For more information about this event, please contact: Charlotte Wu Homme, <u>cwh@oslocancercluster.no</u> or Jutta Heix, <u>jh@oslocancercluster.no</u>

To learn more about Cancer Crosslinks and to register, visit: www.cancercrosslinks.com

Sponsored by:



Lilly







Program

15th Cancer Crosslinks 2023

Thursday, January 26, 2023; Oslo Cancer Cluster Innovation Park, Ullernchausseen 64 – 66, 0379 Oslo

New dimensions to the hallmarks of cancer: How is the last decade of discoveries advancing our understanding of cancer biology and transforming precision medicine?

| From 10:30h | Registration on-site & Log-in for live-stream |
|-------------|--|
| 10:30–10:45 | Opening and Welcome |
| Moderator: | Katarina Puco, Senior Consultant Oncologist at Oslo University Hospital, Institute of Cancer research & Lovisenberg Diaconal Hospital, Oslo and Eli Sihn Samdal Steinskog, Consultant Oncologist, Dept of Oncology, Haukeland University Hospital, Bergen Norway |
| 10:45–11:30 | The Hallmarks of Cancer: New Dimensions - Integrating Pre-Clinical and Clinical Cancer Trials of Mechanism-Targeted Therapies |
| | Douglas Hanahan , Distinguished Scholar of the Ludwig Institute for Cancer Research (Zurich/New York), Professor of Molecular Oncology, Swiss Institute for Experimental Cancer Research of the Swiss Federal Institute of Technology Lausanne, Switzerland (digital talk) |
| 11:30–12:15 | The natural history of non-small cell lung cancer evolution in TRACERx |
| | Mariam Jamal-Hanjani , Group Leader, Cancer Metastasis Lab, CRUK Lung Cancer Centre of Excellence, UCL Cancer Institute; Senior Clinical Lecturer and Honorary Consultant in Translational Lung Oncology, UCL Hospital, London, UK |
| 12:15–13:00 | LUNCH BREAK |
| 13:00–13:35 | Epigenetic (Combination) Therapy – exploiting complex biology to offer novel treatment options for patients with GI cancers |
| | Nilofer Azad , Co-Director of Cancer Genetics and Epigenetics, Professor of Oncology, Johns Hopkins University and Sidney Kimmel Comprehensive Cancer Center, Baltimore, USA (digial talk) |
| 13:35–14:10 | The metabolic regulation of cancer progression |
| | Alpaslan (Aslan) Tasdogan Associate Professor, German Cancer Consortium (DKTK), Institute for Tumor Metabolism, Department of Dermatology, University Hospital Essen, Germany |
| 14:10–14:40 | COFFEE BREAK |
| Moderator: | Anna Pasetto, Associate Professor, Institute of Clinical Medicine, Division of Cancer Medicine, University of Oslo; Director of the Center for Advanced Cell Therapy (ACT) Cancer Clinic, Oslo University Hospital May-Britt Tessem, Associate Professor/Research Scientist, Department of Circulation and Medical Imaging, Faculty of Medicine and Health Sciences, NTNU |
| 14:40–15:15 | Cellular Therapy for solid and hematological tumors: novel targets and technologies Thomas Nerreter, Junior Group Leader, Chair of Cellular Immunotherapy, Translational CAR-T Research Program, University Hospital and CCC Würzburg, Germany |
| 15:15–15:40 | Data-driven hallmarks of acute myeloid leukemia: biological, prognostic & therapeutic implications Tom Erkers , Assistant Professor, Karolinska Institute, Stockholm, Sweden |
| 15:40–16:15 | |
| 15.40-10.15 | Al biomarkers in cancer: recent progress and the way to clinical implementation |
| | Jakob Nikolas Kather , Professor of Clinical Artificial Intelligence, Else Kröner Fresenius Center for Digital Health, Technical University Dresden; Germany |
| 16:15–16:20 | Closing |
| From 16:20 | Networking Session at Oslo Cancer Cluster Innovation Park |